Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.

Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M, Prat A.

Front Oncol. 2019 Sep 25;9:967. doi: 10.3389/fonc.2019.00967. eCollection 2019.

2.

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.

Adamo B, Bellet M, Paré L, Pascual T, Vidal M, Pérez Fidalgo JA, Blanch S, Martinez N, Murillo L, Gómez-Pardo P, López-González A, Amillano K, Canes J, Galván P, González-Farré B, González X, Villagrasa P, Ciruelos E, Prat A.

Breast Cancer Res. 2019 Sep 18;21(1):108. doi: 10.1186/s13058-019-1195-z.

3.

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.

Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M, Prat A.

Front Oncol. 2019 Aug 6;9:707. doi: 10.3389/fonc.2019.00707. eCollection 2019. Erratum in: Front Oncol. 2019 Sep 25;9:967.

4.

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.

Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Sole A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, Prat A, Esteller M, González-Suárez E.

Mol Cancer Res. 2019 Oct;17(10):2063-2076. doi: 10.1158/1541-7786.MCR-19-0040. Epub 2019 Jul 18.

PMID:
31320385
5.

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.

Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.

Cancer Res. 2019 Aug 15;79(16):4258-4270. doi: 10.1158/0008-5472.CAN-18-3835. Epub 2019 Jun 18.

PMID:
31213465
6.

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.

Gluz O, Kolberg-Liedtke C, Prat A, Christgen M, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, Harbeck N.

Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32488. [Epub ahead of print]

PMID:
31162838
7.

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.

Pascual T, Martin M, Fernández-Martínez A, Paré L, Alba E, Rodríguez-Lescure Á, Perrone G, Cortés J, Morales S, Lluch A, Urruticoechea A, González-Farré B, Galván P, Jares P, Rodriguez A, Chic N, Righi D, Cejalvo JM, Tonini G, Adamo B, Vidal M, Villagrasa P, Muñoz M, Prat A.

Front Oncol. 2019 Apr 26;9:303. doi: 10.3389/fonc.2019.00303. eCollection 2019.

8.

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF.

J Natl Cancer Inst. 2019 Apr 30. pii: djz042. doi: 10.1093/jnci/djz042. [Epub ahead of print]

PMID:
31037288
9.

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study.

Guarneri V, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, Orvieto E, Urso L, Pascual T, Paré L, Galván P, Ambroggi M, Giorgi CA, Moretti G, Griguolo G, Vicini R, Prat A, Conte PF.

Ann Oncol. 2019 Feb 18. pii: mdz055. doi: 10.1093/annonc/mdz055. [Epub ahead of print]

10.

Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

Prat A, Brase JC, Cheng Y, Nuciforo P, Paré L, Pascual T, Martínez D, Galván P, Vidal M, Adamo B, Hortobagyi GN, Baselga J, Ciruelos E.

Oncologist. 2019 Jul;24(7):893-900. doi: 10.1634/theoncologist.2018-0407. Epub 2019 Jan 24.

PMID:
30679318
11.

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.

Gavilá J, Oliveira M, Pascual T, Perez-Garcia J, Gonzàlez X, Canes J, Paré L, Calvo I, Ciruelos E, Muñoz M, Virizuela JA, Ruiz I, Andrés R, Perelló A, Martínez J, Morales S, Marín-Aguilera M, Martínez D, Quero JC, Llombart-Cussac A, Prat A.

BMC Med. 2019 Jan 9;17(1):8. doi: 10.1186/s12916-018-1233-1. No abstract available.

12.

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.

Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A.

Ann Oncol. 2018 Oct 1;29(10):2121-2128. doi: 10.1093/annonc/mdy335.

PMID:
30165419
13.

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Paré L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC.

Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2594-E2603. doi: 10.1073/pnas.1717820115. Epub 2018 Feb 23.

14.

GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma.

Moreno M, Pedrosa L, Paré L, Pineda E, Bejarano L, Martínez J, Balasubramaniyan V, Ezhilarasan R, Kallarackal N, Kim SH, Wang J, Audia A, Conroy S, Marin M, Ribalta T, Pujol T, Herreros A, Tortosa A, Mira H, Alonso MM, Gómez-Manzano C, Graus F, Sulman EP, Piao X, Nakano I, Prat A, Bhat KP, de la Iglesia N.

Cell Rep. 2017 Nov 21;21(8):2183-2197. doi: 10.1016/j.celrep.2017.10.083.

15.

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.

Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E.

Ann Oncol. 2018 Jan 1;29(1):170-177. doi: 10.1093/annonc/mdx647.

PMID:
29045543
16.

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

Prat A, Navarro A, Paré L, Reguart N, Galván P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Parker JS, Gaba L, Victoria I, Viñolas N, Vivancos A, Arance A, Felip E.

Cancer Res. 2017 Jul 1;77(13):3540-3550. doi: 10.1158/0008-5472.CAN-16-3556. Epub 2017 May 9.

17.

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.

Gómez-Miragaya J, Palafox M, Paré L, Yoldi G, Ferrer I, Vila S, Galván P, Pellegrini P, Pérez-Montoyo H, Igea A, Muñoz P, Esteller M, Nebreda AR, Urruticoechea A, Morilla I, Pernas S, Climent F, Soler-Monso MT, Petit A, Serra V, Prat A, González-Suárez E.

Stem Cell Reports. 2017 May 9;8(5):1392-1407. doi: 10.1016/j.stemcr.2017.03.026. Epub 2017 Apr 27.

18.

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.

Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, Galván P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Paré L, Alonso I, Albanell J, Vivancos A, González A, Matito J, González S, Fernandez P, Adamo B, Muñoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M.

Oncotarget. 2017 Mar 28;8(13):21930-21937. doi: 10.18632/oncotarget.15748.

19.

Corrigendum re: "TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer" [Eur Urol 2016;70:709-13].

Reig Ò, Marín-Aguilera M, Carrera G, Jiménez N, Paré L, García-Recio S, Gaba L, Pereira MV, Fernández P, Prat A, Mellado B.

Eur Urol. 2017 Aug;72(2):e49. doi: 10.1016/j.eururo.2017.02.027. Epub 2017 Mar 1. No abstract available.

PMID:
28259472
20.

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

Cejalvo JM, Martínez de Dueñas E, Galván P, García-Recio S, Burgués Gasión O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano Á, Muñoz M, Nucíforo P, Vidal M, Pérez RM, Chacón López-Muniz JI, Caballero R, Peg V, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Gomis RR, Lluch A, Prat A.

Cancer Res. 2017 May 1;77(9):2213-2221. doi: 10.1158/0008-5472.CAN-16-2717. Epub 2017 Mar 1.

21.

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A.

Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24.

PMID:
28238593
22.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.

Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.

23.

A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.

Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, de la Haba-Rodríguez J, Arcusa A, Chacón JI, Sánchez-Rovira P, Plazaola A, Muñoz M, Paré L, Parker JS, Ribelles N, Jimenez B, Bin Aiderus AA, Caballero R, Adamo B, Dowsett M, Carrasco E, Martín M, Dixon JM, Perou CM, Alba E.

Clin Cancer Res. 2017 Jun 15;23(12):3035-3044. doi: 10.1158/1078-0432.CCR-16-2092. Epub 2016 Nov 30.

24.

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.

Dieci MV, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V.

Ann Oncol. 2016 Oct;27(10):1867-73. doi: 10.1093/annonc/mdw262. Epub 2016 Aug 2.

PMID:
27484801
25.

Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.

Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S.

JAMA Oncol. 2016 Oct 1;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922.

PMID:
27281556
26.

TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.

Reig Ò, Marín-Aguilera M, Carrera G, Jiménez N, Paré L, García-Recio S, Gaba L, Pereira MV, Fernández P, Prat A, Mellado B.

Eur Urol. 2016 Nov;70(5):709-713. doi: 10.1016/j.eururo.2016.02.034. Epub 2016 Mar 2. Erratum in: Eur Urol. 2017 Aug;72 (2):e49.

PMID:
26948395
27.

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.

Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, Viladot M, Pineda E, Arance A, Muñoz M, Paré L, Cheang MC, Adamo B, Perou CM.

BMC Med. 2015 Dec 18;13:303. doi: 10.1186/s12916-015-0540-z.

28.

Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer.

Gendoo DM, Ratanasirigulchai N, Schröder MS, Paré L, Parker JS, Prat A, Haibe-Kains B.

Bioinformatics. 2016 Apr 1;32(7):1097-9. doi: 10.1093/bioinformatics/btv693. Epub 2015 Nov 24.

29.

Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer.

Cebola I, Custodio J, Muñoz M, Díez-Villanueva A, Paré L, Prieto P, Aussó S, Coll-Mulet L, Boscá L, Moreno V, Peinado MA.

Clin Epigenetics. 2015 Jul 24;7:74. doi: 10.1186/s13148-015-0110-4. eCollection 2015.

30.

Prospective analysis of single operator sonographic optic nerve sheath diameter measurement for diagnosis of elevated intracranial pressure.

Frumin E, Schlang J, Wiechmann W, Hata S, Rosen S, Anderson C, Pare L, Rosen M, Fox JC.

West J Emerg Med. 2014 Mar;15(2):217-20. doi: 10.5811/westjem.2013.9.16191.

31.

Toxic leukoencephalopathy with atypical MRI features following a lacquer thinner fire.

Kao HW, Pare L, Kim R, Hasso AN.

J Clin Neurosci. 2014 May;21(5):878-80. doi: 10.1016/j.jocn.2013.06.027. Epub 2013 Nov 28.

PMID:
24291481
32.

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.

Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, del Río E, Martín-Richard M, Tobeña M, Barnadas A, Baiget M.

Pharmacogenet Genomics. 2013 Mar;23(3):142-7. doi: 10.1097/FPC.0b013e32835d9b0b.

PMID:
23324806
33.

Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.

Altés A, Paré L, Esquirol A, Xicoy B, Rámila E, Vicente L, López R, Orriols J, Vall-llovera F, Sánchez-González B, del Río E, Sureda A, Páez D, Baiget M.

Leuk Lymphoma. 2013 Aug;54(8):1706-12. doi: 10.3109/10428194.2012.752080. Epub 2013 Feb 1.

PMID:
23323945
34.

How core competencies are taught during clinical supervision: participatory action research in family medicine.

Saucier D, Paré L, Côté L, Baillargeon L.

Med Educ. 2012 Dec;46(12):1194-205. doi: 10.1111/medu.12017.

PMID:
23171262
35.

Training in interprofessional collaboration: pedagogic innovation in family medicine units.

Paré L, Maziade J, Pelletier F, Houle N, Iloko-Fundi M.

Can Fam Physician. 2012 Apr;58(4):e203-9.

36.

Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.

Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guinó E, Durán G, Lamas MJ, López R, Candamio S, Gallardo E, Paré L, Baiget M, Páez D, López-Fernández LA, Cortejoso L, García MI, Bujanda L, González D, Gonzalo V, Rodrigo L, Reñé JM, Jover R, Brea-Fernández A, Andreu M, Bessa X, Llor X, Xicola R, Palles C, Tomlinson I, Castellví-Bel S, Castells A, Ruiz-Ponte C, Carracedo A; EPICOLON Consortium.

Pharmacogenomics J. 2013 Jun;13(3):209-17. doi: 10.1038/tpj.2012.2. Epub 2012 Feb 7.

PMID:
22310351
37.

Vertebral artery anomaly causing C2 suboccipital neuralgia, relieved by neurovascular decompression.

Trimble C, Reeves A, Pare L, Tsai F.

J Neuroimaging. 2013 Jul;23(3):421-4. doi: 10.1111/j.1552-6569.2011.00602.x. Epub 2011 Jun 17.

PMID:
21682793
38.

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.

Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, Baiget M.

Br J Cancer. 2011 Jun 28;105(1):53-7. doi: 10.1038/bjc.2011.206. Epub 2011 Jun 7.

39.

Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.

Páez D, Salazar J, Paré L, Pertriz L, Targarona E, del Rio E, Barnadas A, Marcuello E, Baiget M.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1319-27. doi: 10.1016/j.ijrobp.2011.01.025. Epub 2011 May 11.

PMID:
21570215
40.

Interprofessional education at Laval University: Building an integrated curriculum for patient-centred practice.

Bilodeau A, Dumont S, Hagan L, Paré L, Razmpoosh M, Houle N, Brière N, Iloko-Fundi M.

J Interprof Care. 2010 Sep;24(5):524-35. doi: 10.3109/13561821003724026.

PMID:
20718597
41.

Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.

Paré L, Paez D, Salazar J, Del Rio E, Tizzano E, Marcuello E, Baiget M.

Br J Clin Pharmacol. 2010 Aug;70(2):268-72. doi: 10.1111/j.1365-2125.2010.03683.x.

42.

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M.

Cancer Sci. 2010 Sep;101(9):2048-53. doi: 10.1111/j.1349-7006.2010.01621.x.

43.

Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.

Páez D, Paré L, Altés A, Sancho-Poch FJ, Petriz L, Garriga J, Monill JM, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M.

J Cancer Res Clin Oncol. 2010 Nov;136(11):1681-9. doi: 10.1007/s00432-010-0826-7. Epub 2010 Feb 18.

PMID:
20165956
44.

Retroperitoneal transdiaphragmatic robotic-assisted laparoscopic resection of a left thoracolumbar neurofibroma.

Moskowitz RM, Young JL, Box GN, Paré LS, Clayman RV.

JSLS. 2009 Jan-Mar;13(1):64-8.

45.

Primary leptomeningeal oligodendrogliomatosis.

Mathews MS, Paré LS, Kuo JV, Kim RC.

J Neurooncol. 2009 Sep;94(2):275-8. doi: 10.1007/s11060-009-9821-8. Epub 2009 Mar 17.

46.

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.

Ramón y Cajal T, Altés A, Paré L, del Rio E, Alonso C, Barnadas A, Baiget M.

Breast Cancer Res Treat. 2010 Jan;119(1):33-8. doi: 10.1007/s10549-009-0328-y. Epub 2009 Feb 3.

PMID:
19189210
47.

GORE PRECLUDE MVP dura substitute applied as a nonwatertight "underlay" graft for craniotomies: product and technique evaluation.

Chappell ET, Pare L, Salehpour M, Mathews M, Middlehof C.

Surg Neurol. 2009 Jan;71(1):126-8; discussion 128-9. doi: 10.1016/j.surneu.2007.08.041.

PMID:
19084685
48.

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.

Paré L, Marcuello E, Altés A, del Río E, Sedano L, Salazar J, Cortés A, Barnadas A, Baiget M.

Br J Cancer. 2008 Oct 7;99(7):1050-5. doi: 10.1038/sj.bjc.6604671. Epub 2008 Sep 16. Erratum in: Br J Cancer. 2009 Apr 21;100(8):1368.

49.

Spinal angiolipoma: case report and literature review.

Hungs M, Paré LS.

J Spinal Cord Med. 2008;31(3):315-8. Review.

50.

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females.

Paré L, Salazar J, del Rio E, Baiget M, Altés A, Marcuello E, Paez D, Barnadas A.

J Clin Oncol. 2008 Jul 10;26(20):3468; author reply 3468-9. doi: 10.1200/JCO.2008.17.6479. No abstract available.

PMID:
18612168

Supplemental Content

Support Center